C-CAMP announces strategic tie up with Agilent to boost access to advanced life sciences innovation in biopharma, biologics and vaccines
The Centre for Cellular and Molecular Platforms (C-CAMP) has announced the expansion and augmentation of its long-standing collaboration with Agilent Technologies, a global leader in cutting-edge bio analytics and biotechnology platforms.
The second phase of this partnership will broaden shared access to advanced analytical and mass spectrometry-based capabilities supporting life sciences and therapeutics research in India.
With a strong global mandate to drive science-led innovation that addresses tomorrow’s challenges, C-CAMP is committed to advancing frontier science and deep-tech innovation.
C-CAMP has consistently collaborated with global leaders to enable cutting-edge solutions and translate breakthrough science into real-world impact.
Access advanced analytical workflows:
The expanded collaboration focuses on making high‑resolution analytical platforms available through C‑CAMP’s shared infrastructure, supporting applications such as biotherapeutic characterisation, oligonucleotide research, and quantitative biomolecular analysis.
The model is designed to enable researchers from startups, academia and industry to access advanced analytical workflows and deep scientific knowhow without the need for direct capital investment in specialised instrumentation or facilities.
As India continues to strengthen its focus on translational research and the development of advanced therapeutics, access to high‑quality analytical infrastructure has become increasingly critical. Through this collaboration, Agilent and C‑CAMP aim to help reduce entry barriers and support reliable, reproducible science across the research and development continuum.
C-CAMP Biopharma Characterisation Facility:
The C-CAMP Biopharma Characterisation Facility, BCF with the support of Agilent Technologies has already facilitated the development and regulatory clearance of several key biomolecules in therapeutics and vaccines that have been manufactured end-to-end in India.
One of the major milestones from the phase I of this collaboration includes the LC/MS-based characterisation of Liraglutide, a GLP-1 agonist used in diabetes and obesity management, using Agilent’s Mass Spectrometry platform. This research is a game-changer for therapeutic peptide development, ensuring compliance with FDA safety standards & enhancing drug efficacy.
Building on this momentum, the expanded collaboration deepens C‑CAMP and Agilent’s shared commitment to accelerating next‑generation biotherapeutics.
Quotes:
Dr. Taslimarif Saiyed, Director and CEO, C‑CAMP, said: “Partnerships with frontier science and technology leaders such as Agilent will help C-CAMP build cutting-edge capabilities in India to support researchers and innovators across the country. In the coming years, we believe such collaborations will play a key role in enabling technology development and accelerating science-led innovation. The engagement also aligns with C-CAMP’s vision of building a connected ecosystem that supports science-to-impact pathways, while leveraging Agilent’s expertise in analytical workflows and technology enablement.”
Nandakumar Kalathil, Country General Manager, Agilent India added: “India is a strategic priority for Agilent, and partnerships like this are central to how we expand access to critical scientific capabilities. Working with C‑CAMP allows a broader community of researchers to leverage advanced analytical workflows that support high‑quality, reproducible science across discovery and translational research.”
Bharat Bhardwaj, Vice President and General Manager, Asia Pacific, Agilent Technologies, mentioned, “Across Asia Pacific, we are seeing a strong shift toward collaborative, shared infrastructure models that enable broader participation in advanced scientific research. Our expanded engagement with C CAMP reflects Agilent’s commitment to building inclusive innovation ecosystems—where startups, academia, and industry can accelerate high quality research and translate science into meaningful impact.”
Joint efforts will kick off with a focused training programme designed to equip scientists from startups and industry with the skills to assess critical quality attributes (CQAs) in biopharmaceutical development using high- resolution LC-MS/MS.
